• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Tuesday

    7/25/23 12:33:02 PM ET
    $ACGN
    $ADCT
    $AIRG
    $ALT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACGN alert in real time by email

     

    On Tuesday, 56 companies set new 52-week lows.

    Noteworthy Highlights From Today's 52-Week Lows:

    • The largest company by market cap to set a new 52-week low was Apellis Pharmaceuticals (NASDAQ:APLS).
    • 9 Meters Biopharma (NASDAQ:NMTR) was the smallest company by market cap to set a new 52-week low.
    • Humanigen (NASDAQ:HGEN)'s stock came under the most pressure, trading down 73.22% to reach a new 52-week low.
    • NeuBase Therapeutics (NASDAQ:NBSE) saw the biggest bounce back on, as shares traded up 0.0% to rebound after it hit its new 52-week low.

    On Tuesday, the following stocks set new 52-week lows:

    • Apellis Pharmaceuticals (NASDAQ:APLS) stock drifted down 2.25% on Tuesday morning to hit a new 52-week low of $31.23.
    • Silicon Motion Technology (NASDAQ:SIMO) stock hit a new 52-week low of $51.44. The stock was down 1.3% on the session.
    • Park Ntl (AMEX:PRK) stock dropped to a yearly low on Tuesday of $90.28. Shares traded down 6.01%.
    • Avidity Biosciences (NASDAQ:RNA) stock hit $9.29 on Tuesday morning, setting a new 52-week low for a change of down 3.79%.
    • IDT (NYSE:IDT) stock set a new 52-week low of $23.08 on Tuesday, moving down 0.98%.
    • Vertex Energy (NASDAQ:VTNR) shares hit a yearly low of $5.11. The stock was down 21.54% on the session.
    • uniQure (NASDAQ:QURE) shares fell to $9.64 on Tuesday, setting a new 52-week low with a shift of down 0.1%.
    • TrueBlue (NYSE:TBI) stock set a new 52-week low of $13.52 on Tuesday, moving down 20.83%.
    • PSQ Holdings (NYSE:PSQH) shares set a new 52-week low of $15.51. The stock traded down 5.28%.
    • Erasca (NASDAQ:ERAS) stock drifted down 3.28% on Tuesday morning to hit a new 52-week low of $2.46.
    • Rimini Street (NASDAQ:RMNI) shares moved down 31.95% on Tuesday to hit a new 52-week low of $3.21, drifting down 31.95%.
    • Stoke Therapeutics (NASDAQ:STOK) shares hit a yearly low of $6.17. The stock was down 33.68% on the session.
    • NGM Biopharmaceuticals (NASDAQ:NGM) stock hit $2.38 on Tuesday morning, setting a new 52-week low for a change of down 4.4%.
    • Inogen (NASDAQ:INGN) stock hit a new 52-week low of $8.22. The stock was up 1.09% on the session.
    • Kezar Life Sciences (NASDAQ:KZR) stock set a new 52-week low of $2.21 on Tuesday, moving down 0.44%.
    • Altimmune (NASDAQ:ALT) shares fell to $3.02 on Tuesday, setting a new 52-week low with a shift of down 1.25%.
    • Beyond Air (NASDAQ:XAIR) stock broke to a new 52-week low of $3.53 on Tuesday. Shares of the company traded down 3.27%.
    • ADC Therapeutics (NYSE:ADCT) shares set a new 52-week low of $1.22. The stock traded up 0.3%.
    • CEL-SCI (AMEX:CVM) shares set a new 52-week low of $1.72. The stock traded down 5.88%.
    • Airgain (NASDAQ:AIRG) shares were down 2.91% for the day, having made a 52-week low of $4.62.
    • Destra Multi-Alternative (NYSE:DMA) shares fell to $4.78 on Tuesday, setting a new 52-week low with a shift of down 0.41%.
    • CBL International (NASDAQ:BANL) shares hit a yearly low of $1.64. The stock was down 12.18% on the session.
    • Eledon Pharma (NASDAQ:ELDN) shares hit a yearly low of $1.26. The stock was down 1.54% on the session.
    • Purple Biotech (NASDAQ:PPBT) shares reached a new 52-week low of $1.17 on Tuesday morning, moving up 0.13%.
    • Vaccinex (NASDAQ:VCNX) stock set a new 52-week low of $0.28 on Tuesday, moving down 1.49%.
    • Geovax Labs (NASDAQ:GOVX) shares set a new 52-week low of $0.53. The stock traded down 4.2%.
    • AERWINS Technologies (NASDAQ:AWIN) shares set a new yearly low of $0.22 this morning. The stock was down 3.94% on the session.
    • Cadrenal Therapeutics (NASDAQ:CVKD) shares set a new yearly low of $1.01 this morning. The stock was down 3.62% on the session.
    • Greenbrook TMS (NASDAQ:GBNH) shares set a new 52-week low of $0.30. The stock traded down 8.88%.
    • 60 Degrees (NASDAQ:SXTP) shares set a new yearly low of $2.13 this morning. The stock was down 7.23% on the session.
    • BioRestorative Therapies (NASDAQ:BRTX) shares were down 9.4% for the day, having made a 52-week low of $2.33.
    • Bio-Path Hldgs (NASDAQ:BPTH) stock achieved a new 52-week low on Tuesday morning, hitting $0.96 and moving down 7.87%.
    • Titan Pharma (NASDAQ:TTNP) stock hit $0.51 on Tuesday morning, setting a new 52-week low for a change of up 0.37%.
    • Cyclerion Therapeutics (NASDAQ:CYCN) stock dropped to a yearly low on Tuesday of $3.19. Shares traded down 4.14%.
    • Lixte Biotech Hldgs (NASDAQ:LIXT) shares made a new 52-week low of $3.82 on Tuesday. The stock was down 1.53% for the day.
    • Cingulate (NASDAQ:CING) stock broke to a new 52-week low of $0.60 on Tuesday. Shares of the company traded down 15.06%.
    • ViewRay (NASDAQ:VRAY) stock achieved a new 52-week low on Tuesday morning, hitting $0.03 and moving down 10.58%.
    • Humanigen (NASDAQ:HGEN) stock drifted down 73.22% on Tuesday morning to hit a new 52-week low of $0.05.
    • Mallinckrodt (AMEX:MNK) shares moved down 0.96% on Tuesday to hit a new 52-week low of $0.43, drifting down 0.96%.
    • Aceragen (NASDAQ:ACGN) stock drifted down 7.38% on Tuesday morning to hit a new 52-week low of $0.66.
    • Soligenix (NASDAQ:SNGX) stock drifted down 1.55% on Tuesday morning to hit a new 52-week low of $0.60.
    • SuperCom (NASDAQ:SPCB) shares hit a yearly low of $0.76. The stock was up 0.89% on the session.
    • C3is (NASDAQ:CISS) stock hit $0.63 on Tuesday morning, setting a new 52-week low for a change of down 3.16%.
    • Avalo Therapeutics (NASDAQ:AVTX) stock broke to a new 52-week low of $0.22 on Tuesday. Shares of the company traded down 10.06%.
    • NeuBase Therapeutics (NASDAQ:NBSE) stock drifted 0.0% (flat) on Tuesday morning to hit a new 52-week low of $1.50.
    • Altamira Therapeutics (NASDAQ:CYTO) shares fell to $0.33 on Tuesday, setting a new 52-week low with a shift of down 0.75%.
    • BitNile Metaverse (NASDAQ:BNMV) shares hit a yearly low of $0.90. The stock was down 2.92% on the session.
    • Esports Entertainment (NASDAQ:GMBL) stock hit a yearly low of $0.51. The stock was down 4.04% for the day.
    • 9 Meters Biopharma (NASDAQ:NMTR) shares moved down 14.45% on Tuesday to hit a new 52-week low of $0.10, drifting down 14.45%.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ACGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACGN
    $ADCT
    $AIRG
    $ALT

    CompanyDatePrice TargetRatingAnalyst
    Stoke Therapeutics Inc.
    $STOK
    2/5/2026$60.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    uniQure N.V.
    $QURE
    1/28/2026$31.00Equal Weight
    Barclays
    Apellis Pharmaceuticals Inc.
    $APLS
    1/28/2026$24.00Equal Weight
    Barclays
    Altimmune Inc.
    $ALT
    1/28/2026$20.00Overweight
    Barclays
    Erasca Inc.
    $ERAS
    1/27/2026$16.00Outperform
    Mizuho
    Silicon Motion Technology Corporation
    $SIMO
    1/22/2026Outperform
    William Blair
    Airgain Inc.
    $AIRG
    1/21/2026$6.00Buy
    Lake Street
    More analyst ratings

    $ACGN
    $ADCT
    $AIRG
    $ALT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

    ~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~ ~ Stable Lyso-Gb3 levels maintained post-dosing, regardless of enzyme replacement therapy status across all cohorts ~ ~ Six of 11 patients have discontinued enzyme replacement therapy as of data cutoff date ~ LEXINGTON, Mass. and AMSTERDAM, Feb. 06, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated preliminary safety and exploratory efficacy data from 11 patients in its Phase I/IIa trial of AMT-191, an investigational AAV gene

    2/6/26 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

    IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that Steven Perrin, Ph.D., President and Chief Scientific Officer will participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 10:00 a.m. ET (7:00 a.m. PT). To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company's website under Events. About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the m

    2/5/26 4:10:11 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Message from Dusty Wunderlich, President & CEO of PSQ Holdings

    PSQ Holdings, Inc. (NYSE:PSQH) today issued the following letter to shareholders: February 5, 2026 To Our Shareholders Four weeks ago, I stepped into the role of Chairman. Last week, I assumed the additional responsibility of Chief Executive Officer. While I previously served as Chief Strategy Officer prior to this transition, these new roles require a different posture, one grounded in direct accountability for execution, capital allocation, and results. Since taking on these responsibilities, I have spent time assessing the business with fresh discipline. Not through headlines or short-term sentiment, but by examining the fundamentals. Durable companies are not built by reacting t

    2/5/26 8:00:00 AM ET
    $PSQH
    Advertising
    Consumer Discretionary

    $ACGN
    $ADCT
    $AIRG
    $ALT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Stoke Therapeutics with a new price target

    Guggenheim initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $60.00

    2/5/26 6:58:02 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on uniQure with a new price target

    Barclays initiated coverage of uniQure with a rating of Equal Weight and set a new price target of $31.00

    1/28/26 7:20:10 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $ADCT
    $AIRG
    $ALT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-5) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:04:01 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-4) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:03:14 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $ACGN
    $ADCT
    $AIRG
    $ALT
    SEC Filings

    View All

    SEC Form S-1 filed by BioRestorative Therapies Inc.

    S-1 - BioRestorative Therapies, Inc. (0001505497) (Filer)

    2/9/26 5:31:45 PM ET
    $BRTX
    Managed Health Care
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Kezar Life Sciences Inc.

    SCHEDULE 13G/A - Kezar Life Sciences, Inc. (0001645666) (Subject)

    2/9/26 2:39:13 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by uniQure N.V.

    SCHEDULE 13G - uniQure N.V. (0001590560) (Subject)

    2/9/26 8:10:32 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $ADCT
    $AIRG
    $ALT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kersten Geert R bought $200,001 worth of shares (38,023 units at $5.26), increasing direct ownership by 46% to 120,815 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    1/26/26 8:23:27 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Pisano Wayne bought $20,410 worth of shares (5,000 units at $4.08), increasing direct ownership by 59% to 13,498 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    1/9/26 4:10:05 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sohn Catherine A. bought $2,118 worth of shares (500 units at $4.24), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    1/5/26 4:05:39 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $ADCT
    $AIRG
    $ALT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP; President - PeopleScout Betori Richard P. covered exercise/tax liability with 379 shares, decreasing direct ownership by 0.37% to 101,401 units (SEC Form 4)

    4 - TrueBlue, Inc. (0000768899) (Issuer)

    2/6/26 9:27:34 AM ET
    $TBI
    Professional Services
    Consumer Discretionary

    CEO and President Owen Taryn R covered exercise/tax liability with 5,250 shares, decreasing direct ownership by 1% to 403,259 units (SEC Form 4)

    4 - TrueBlue, Inc. (0000768899) (Issuer)

    2/5/26 6:47:43 PM ET
    $TBI
    Professional Services
    Consumer Discretionary

    Chief Executive Officer Francois Cedric exercised 8,840 shares at a strike of $3.76, increasing direct ownership by 2% to 490,837 units (SEC Form 4)

    4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

    2/5/26 4:14:07 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $ADCT
    $AIRG
    $ALT
    Leadership Updates

    Live Leadership Updates

    View All

    PublicSquare Appoints Dusty Wunderlich as Chief Executive Officer

    New Leadership Reinforces Progress Toward Fintech Focus PSQ Holdings, Inc. (NYSE:PSQH) ("PublicSquare" or the "Company"), today announced that Dusty Wunderlich has been appointed CEO, effective immediately, as the Company continues its transition to core fintech businesses, including credit and payments. Mr Wunderlich was recently appointed Chairman of the Board of PublicSquare and will remain in that role. As part of this transition, Michael Seifert has stepped down as Chief Executive Officer and resigned from the Company's Board of Directors, effective January 27, 2026. Mr. Wunderlich was CEO of Credova until PublicSquare acquired the company in March 2024. Given his fintech experienc

    1/29/26 7:30:00 AM ET
    $PSQH
    Advertising
    Consumer Discretionary

    TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc

    1/27/26 6:02:00 PM ET
    $AEIS
    $AHR
    $AMRX
    Industrial Machinery/Components
    Technology
    Real Estate Investment Trusts
    Real Estate

    Airgain® Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Airgain, Inc. (NASDAQ:AIRG), a leading provider of advanced wireless connectivity solutions, today announced that it has granted inducement awards to one new employee who recently joined the Company. The awards were made on December 15, 2025, under Airgain's 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Airgain as an inducement to join the company. The inducement awards to the new employee consist of an aggregate of 1,150 restricted stock units ("RSUs"). The RSUs shall vest over four years in substantially equal annual installments on December 15, 2026, 2027, 2028, and 2029, subject to the employee's continued service

    12/15/25 4:05:00 PM ET
    $AIRG
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ACGN
    $ADCT
    $AIRG
    $ALT
    Financials

    Live finance-specific insights

    View All

    Airgain Sets Fourth Quarter and Full Year 2025 Conference Call for Thursday, February 26, at 5:00 p.m. ET

    Airgain, Inc. (NASDAQ:AIRG), a leading provider of advanced wireless connectivity solutions, will hold a conference call on Thursday, February 26, 2026, at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to discuss its financial results for the fourth quarter and year ended December 31, 2025. Airgain management will host the presentation, followed by a question-and-answer period. Date: Thursday, February 26, 2026 Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time) Participant Dial-In: 877-407-2988 / +1 201-389-0923 or Call Me Event Confirmation #: 13757859 The conference call will be broadcast simultaneously and available for replay via the investor section of the company's website

    2/5/26 8:00:00 AM ET
    $AIRG
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Silicon Motion Announces Results for the Fourth Quarter and Year Ended December 31, 2025

    Business Highlights Fourth quarter of 2025 sales increased 15% Q/Q and increased 46% Y/Y SSD controller sales: 4Q of 2025 increased 25% to 30% Q/Q and increased 35% to 40% Y/YeMMC+UFS controller sales: 4Q of 2025 increased 0% to 5% Q/Q and increased 50% to 55% Y/YSSD solutions sales: 4Q of 2025 increased 125% to 130% Q/Q and increased 110% to 115% Y/Y Announced annual cash dividend of $2.00 per American Depositary Share ("ADS") Financial Highlights  4Q 2025 GAAP4Q 2025 Non-GAAP*•   Net sales$278.5 million (+15% Q/Q, +46% Y/Y)$278.5 million (+15% Q/Q, +46% Y/Y)•   Gross margin49.1%49.2%•   Operating margin11.4%19.3%•   Earnings per diluted ADS$1.41$1.26  Full Year 2025 GAAPFull Year 2025 N

    2/3/26 6:00:00 PM ET
    $SIMO
    Semiconductors
    Technology

    Silicon Motion Confirms Quarterly Dividend

    TAIPEI, Taiwan and MILPITAS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Silicon Motion Technology Corporation (NASDAQ:SIMO) ("Silicon Motion" or the "Company"), a global leader in designing and marketing NAND flash controllers for solid state storage devices, confirms today its quarterly cash dividend. On October 27, 2025, the Board of Directors of the Company declared payment of an annual dividend of US$2.00 per ADS1, equivalent to US$0.50 per ordinary share, which will be paid in four quarterly installments of $0.50 per ADS, equivalent to US$0.125 per ordinary share. According to the previously announced record and payment dates, the next quarterly installment will be paid on February 26

    2/2/26 8:00:00 AM ET
    $SIMO
    Semiconductors
    Technology

    $ACGN
    $ADCT
    $AIRG
    $ALT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PSQ Holdings Inc.

    SC 13G - PSQ Holdings, Inc. (0001847064) (Subject)

    12/12/24 11:50:43 AM ET
    $PSQH
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

    SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 8:47:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care